Spark Therapeutics Competitors and Similar CompaniesClear all
Spark Therapeutics's competitors and similar companies include ImmusanT, Human Stem Cells Institute and Genclis.
 ImmusanT ImmusanT is a clinical development-stage biotechnology company focused on an innovative disease-modifying approach to induce immune tolerance in autoimmune diseases. |  Human Stem Cells Institute Human Stem Cells Institute is a biomedical technologies and healthcare solutions provider. |  Genclis Genclis is a biotechnology company focused on developing therapies for both human and animal health using Transcription Infidelity (TI). | ||
Founding Date | Founding Date 2013 | Founding Date 2010 | Founding Date 2003 | Founding Date 2004 |
Type | Type Public | Type Private | Type Public | Type Private |
Tags | ||||
Locations | Locations Philadelphia, US HQ | Locations Cambridge, US HQ | Locations Moscow, RU HQ | Locations Vandœuvre-lès-Nancy, FR HQ |
Employees | Employees 36817% increase | Employees 2 | Employees N/A | Employees 6 |
Financial | ||||
Revenue (est.) | Revenue (est.) $64.7m (FY, 2018) | Revenue (est.) N/A | Revenue (est.) ₽1.7b (FY, 2025) | Revenue (est.) N/A |
Net income | Net income ($78.8m) (FY, 2018) | Net income N/A | Net income ₽107.7m (FY, 2025) | Net income N/A |
Funding | ||||
Total funding raised | Total funding raised $ 122.8m | Total funding raised $ 72.8m | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
ImmusanT
HQ
Cambridge, US
Employees
2
ImmusanT is a clinical development-stage biotechnology company focused on an innovative disease-modifying approach to induce immune tolerance in autoimmune diseases.
View companyHuman Stem Cells Institute
HQ
Moscow, RU
Human Stem Cells Institute is a biomedical technologies and healthcare solutions provider.
View companyGenclis
HQ
Vandœuvre-lès-Nancy, FR
Employees
6
Genclis is a biotechnology company focused on developing therapies for both human and animal health using Transcription Infidelity (TI).
View company